Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Pharmacyclics Still on a Roll After Earnings Results

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

It's been a big week for Pharmacyclics (UNKNOWN: PCYC.DL  ) . On Tuesday, the small biotech announced that the Food and Drug Administration had granted Breakthrough Therapy Designation to ibrutinib for the treatment of relapsed or refractory mantle cell lymphoma, or MCL, and for the treatment of Waldenstrom's macroglobulinemia. The company also released quarterly results after the market closed on Thursday. Here are the highlights from those results.

Pharmacyclics reported net income for the quarter ending Dec. 31, 2012 of $41.9 million, or $0.56 per diluted share. This figure was lower than the $0.78 per diluted share from the same quarter in 2011 but beat average analyst expectations of $0.31 per share. On a non-GAAP basis, the company said that earnings per share for the quarter was $0.62 per diluted share compared with $0.82 per diluted share in the prior year.

Revenue for the quarter came in at $58 million -- less than the $77.9 million reported in the same quarter of 2011. Pharmacyclics' major partner on ibrutinib, Johnson & Johnson's (NYSE: JNJ  ) Janssen unit, contributed $50 million of that revenue total. Another $5 million came from Novo Nordisk A/S (NYSE: NVO  ) . The larger pharmaceutical company bought the rights for Pharmacyclics' small molecule Factor VIIa inhibitor, PCI-27483 for use outside of oncology.

All of the key numbers were down from the same quarter in 2011 because fewer milestone payments were received and expenses were higher. That's not necessarily bad news at this stage in the game for Pharmacyclics, though. Milestone payments can be lumpy, coming at irregular intervals. And the higher expenses are a direct result of moving things along more quickly with clinical studies and research and development.

Looking ahead
The future for Pharmacyclics, for now at least, is all about ibrutinib. A grand total of 27 different clinical trials are registered for the drug with the National Institute of Health. Gaining Breakthrough Designation from the FDA is a big deal, allowing the company a faster path to ultimate approval and commercialization of the drug.

Pharmacyclics is also in the nice position of not having to worry too much about cash, a problem many small biotechs face. It has a stockpile of more than $317 million in cash and equivalents. Even better, Janssen funds much of the development for ibrutinib. Pharmacyclics projects that it will finish this year with more than $225 million in cash despite increasing expenses.

Five phase 3 trials are under way for ibrutinib. None of these will finish in 2013, but this will be an important year for Pharmacyclics. Shares are up over 30% year to date, including a nice 4% bump in trading on Friday after the earnings announcement. This was a big week for the company. I expect there will be plenty more big weeks ahead. 

2013 should be a big year for Pharmacyclics, but The Motley Fool's chief investment officer thinks it could be an even bigger year for this stock. Find out which stock he selected as the No. 1 position in our brand-new free report: "The Motley Fool's Top Stock for 2013." I invite you to take a copy, free for a limited time. Just click here to access the report and find out the name of this under-the-radar company.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2260078, ~/Articles/ArticleHandler.aspx, 9/25/2016 10:26:31 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 2 days ago Sponsored by:
DOW 18,261.45 -131.01 -0.71%
S&P 500 2,164.69 -12.49 -0.57%
NASD 5,305.75 -33.78 -0.63%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/31/1969 7:00 PM
PCYC.DL $0.00 Down +0.00 +0.00%
JNJ $118.81 Down -0.65 -0.54%
Johnson and Johnso… CAPS Rating: *****
NVO $44.88 Down -0.69 -1.51%
Novo Nordisk CAPS Rating: *****